Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC-CIK Therapy in Renal Cell Carcinoma
NCT02487550Phase 2Not yet recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Aug 2015
- Primary completion
- Jul 2028
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of dendritic cell vaccine + cytokine-induced killer cells in renal cell carcinoma (RCC), sponsored by Changzhou First People's Hospital. Planned start Aug 2015; status: not yet recruiting.
02
Drugs
dendritic cell vaccine + cytokine-induced killer cells
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02487550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02487550.